DCP1A and pheochromocytoma: Consistent with the above results, we found that expression levels of DCP1a were reduced in various cancers: bladder urothelial carcinoma, uterine corpus endometrial carcinoma, head and neck squamous cell carcinoma, prostate adenocarcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung squamous cell carcinoma, kidney renal clear cell carcinoma, breast invasive carcinoma, thyroid carcinoma, lung adenocarcinoma, pheochromocytoma and paraganglioma, and thymoma.